| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Jun―23 |
Corrigendum to “A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2” [Antivir. Res. 225 (2024) 105854] |
Weiqi Wang, Shen Wang, Xianyong Meng, Yongkun Zhao, Nan Li, Tiecheng Wang, Na Feng, Feihu Yan, Xianzhu Xia |
| 2 |
[GO] |
2026―May―22 |
Identification of Nsp15 Inhibitors Restoring Interferon-Dependent Antiviral Activity Against SARS-CoV-2 |
Stefania Maloccu, Yuka Otsuka, Elizabeth Molchan, Michelle Foti, Annalaura Paulis, Jyoti Vishwakarma, Paolo Malune, Filippo Cottiglia, Angela Corona, Louis Scampavia, Timothy P. Spicer, Reuben S. Harris, Enzo Tramontano, Elisa Fanunza |
| 3 |
[GO] |
2026―May―19 |
Cell-Type Specific Effects of SARS-CoV-2 P252L Mutation on Nirmatrelvir Sensitivity |
Sheryline Loison, Mehdi Chabert, Constant Gensous, Samuel Constant, Song Huang, Caroline Tapparel, Sophie Clément |
| 4 |
[GO] |
2026―May―19 |
LTX-109 as a broad-spectrum antiviral: in vitro and in vivo efficacy against SARS-CoV-2 and Influenza Viruses |
Matteo Pagliari, Christian Lütken, Lucrezia Vianello, Elisa Mazzacan, Daniele Facco, Sami Ramzi, Giovanni Restano, Francesco Bonfante |
| 5 |
[GO] |
2026―Mar―02 |
FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo |
Gudepalya Renukaiah Rudramurthy, Chandra Sekhar Gudla, Rajappa Harisha, Vignesh Selvam, Likhitha Kodihalli Vijayakumar, Varun Kailaje, Chakenahalli Naveenkumar, Kumaraswamy Bharathkumar, Siva Shanmugam, Rohan Narayan, Aditi Kanojia, Shashank Tripathi, Ankush Roy, Vidya Mangala Prasad, Tanvi Sharad, Shwetha Shivaprasad, Ravinder Reddy Kondreddi, Mayas Singh, Radha Krishan Shandil, Shridhar Narayanan |
| 6 |
[GO] |
2026―Feb―19 |
Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m6A enzymatic activity |
Ting Zhang, Zi-Ling Wang, Xi-Ya Li, Rong-Hua Luo, Lu-Xi Zhang, Hong-Yi Zheng, Si-Dong Xiong, Wen-Lan Yang, Yong-Tang Zheng |
| 7 |
[GO] |
2026―Feb―09 |
Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals |
Francesca Toselli, Sofie Jacobs, Els Scheers, Tom Jacobs, Jordi Doijen, Joyce Hereijgers, Ken Keustermans, Liese Aerts, Marjolein van Heerden, Marnix Van Loock, Stephen Mason, Mario Monshouwer, Ellen Van Damme, Florence Herschke |
| 8 |
[GO] |
2026―Jan―30 |
Analysis of Ibuzatrelvir’s Activity Against SARS-CoV-2 Circulating Variants and In Vitro Resistance Mutations |
Irina Yurgelonis, Devendra K. Rai, Zhenghui Li, Brittany Washington, Patricia McMonagle, Stephen Noell, Olga Plotnikova, Jennifer Nicki, Timothy K. Craig, Qingyi Yang, Elizabeth Titova, Kwok Lee, Mohammad Amin Behzadi, Hussin Rothan, Ha H. Nguyen, Todd Coffey, Jonathan T. Lee, Yuao Zhu, Li Hao, Barry N. Kreiswirth, Rhonda D. Cardin, Charlotte M.N. Allerton, Isabel Najera |
| 9 |
[GO] |
2026―Jan―19 |
SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19 |
Charlotte Hedskog, Lauren Rodriguez, Yu Hu, Jiani Li, Dong Han, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jason K. Perry, Juan Maria González Del Castillo, Yiannis Koullias, Ross Martin, Robert H. Hyland |
| 10 |
[GO] |
2025―Dec―29 |
SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19 |
Lauren Rodriguez, Yu Hu, Jiani Li, Dong Han, Nadine Peinovich, Clarissa Martinez, Pui Yan Ho, Jason K. Perry, Ross Martin, Onyema Ogbuagu, Amos Lichtman, Robert H. Hyland, Charlotte Hedskog |
| 11 |
[GO] |
2025―Dec―06 |
Poly (allylamine hydrochloride)-selenium Nanoparticles Inhibit Porcine Reproductive and Respiratory Syndrome Virus by Targeting DDX5 and Reactive Oxygen Species |
Wenqiao Yang, Yuan Xu, Runmin Kang, Min Zhang, Yuting Zhang, Zeng Yang, Huiyuan Jing, Yilin Liu, Jiaxiang Li, Yongjie Ge, Haibo Feng, Long Zhou, Jiang Pi, Jie Liu |
| 12 |
[GO] |
2025―Nov―04 |
A dual-reporter HCoV-OC43 for coronavirus biology and countermeasure development |
Xiangxue Deng, Jing Zou, Zhenjie Liang, Ping Ren, Pei-Yong Shi, Vineet D. Menachery, Xuping Xie |
| 13 |
[GO] |
2025―Sep―03 |
DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection |
Chenxi Zhu, Ziqiao Wang, Zhendong Pan, Xinjia Mai, Yiyun Chen, Wen Zhang, Ping Zhao, Hailin Tang, Rong Zhang, Dapeng Zhou |
| 14 |
[GO] |
2025―Sep―02 |
Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters |
Ryoichi Tashima, Takayuki Kuroda, Haruaki Nobori, Satoshi Miyagawa, Takuya Yamane, Alice Shimba, Masaaki Nakashima, Keita Fukao |
| 15 |
[GO] |
2025―Aug―29 |
An engineered chimeric ACE2-HR2 peptide exhibits potent and broad-spectrum activity against SARS-CoV-2 variants |
Wenwen Bi, Tao Zhu, Yawen Xu, Yihui Chen, Jianmin Li |
| 16 |
[GO] |
2025―Aug―28 |
Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases |
Takaya Ichikawa, Tomokazu Tamura, Naganori Nao, Hikoyu Suzuki, Shuhei Maruyama, Daiki Wada, Shuhei Tsujino, Noriyoshi Yoshinaga, Kohsuke Asagoe, Mutsumi Takahata, Takashi Ishio, Makoto Ibata, Tanino Yoko, Yasutaka Kakinoki, Kazuhiro Okubo, Rigel Suzuki, Saori Suzuki, Yasushi Nakamori, Takanori Teshima, Takasuke Fukuhara |
| 17 |
[GO] |
2025―Aug―18 |
Viral Determinants of Cis- and Trans-Cleavage by SARS-CoV-2 Nsp3 and an On-Off Reporter for Monitoring Intracellular Protease Activity |
Fuzhi Lei, Jun Shu, Chengjie Xia, Yahan Lei, Yajie Zhang, Yang Zhang, Zhenghong Yuan, Zhigang Yi |
| 18 |
[GO] |
2025―Aug―18 |
SMAD5 phosphorylation by ALK1 is modulated by the interaction of the spike protein of SARS-CoV-2 and angiotensin-converting enzyme 2 |
Yoichi Teratake, Tadashi Okamura, Yukihito Ishizaka |
| 19 |
[GO] |
2025―Aug―05 |
Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 Replication |
Guoqiang Yao, Xue Shi, Hao Jiang, Anna Duan, Jiancun Zhang |
| 20 |
[GO] |
2025―Jul―29 |
The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication |
Doha Al Krad, Kim M. Stegmann, Antje Dickmanns, Priya Kumar, Claudia Blaurock, Björn-Patrick Mohl, Sina Jasmin Wille, Angele Breithaupt, Tobias Britzke, Anne Balkema-Buschmann, Matthias Dobbelstein |
| 21 |
[GO] |
2025―Jul―15 |
SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibody |
Mikhail Lebedin, Nikolai Petrovsky, Kairat Tabynov, Kaissar Tabynov, Yuri Lebedin |
| 22 |
[GO] |
2025―Jun―03 |
Unveiling SARS-CoV-2's heart: role, structure and inhibition of SARS-CoV-2 RNA-dependent RNA polymerase |
Paolo Malune, Francesca Esposito, Enzo Tramontano |
| 23 |
[GO] |
2025―Apr―22 |
ISAR opinion: Product development partnerships to fund pandemic antiviral research |
Luis M. Schang |
| 24 |
[GO] |
2025―Mar―21 |
Corrigendum to “IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility” [Antiv. Res. (2025) 106082] |
Mengxin Xu, Zhaoyong Zhang, Yuzhu Sun, Haoting Mai, Siqi Liu, Shuning Liu, Kexin Lv, Feiyang Yu, Yuanyuan Wang, Xinyu Yue, Jiayi Zhang, Xiaoyu Cai, Ruixin Zhao, Hongjie Lu, Lin Liu, Huanle Luo, Haiyan Zhao, Yanqun Wang, Peng Gong, Shoudeng Chen, Xuping Jing, Jincun Zhao, Yao-Qing Chen |
| 25 |
[GO] |
2025―Mar―04 |
Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2 |
Blandine Padey, Clément Droillard, Victoria Dulière, Julien Fouret, Claire Nicolas de Lamballerie, Cédrine Milesi, Emilie Laurent, Pauline Brun, Aurélien Traversier, Thomas Julien, Olivier Terrier, Manuel Rosa-Calatrava, Andrés Pizzorno |
| 26 |
[GO] |
2025―Feb―23 |
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals |
Juliane Brun, Benediktus Yohan Arman, Michelle L. Hill, J.L. Kiappes, Dominic S. Alonzi, Laetitia L. Makower, Karolina D. Witt, Carina Gileadi, Victor Rangel, Raymond A. Dwek, Annette von Delft, Nicole Zitzmann |
| 27 |
[GO] |
2025―Feb―07 |
Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment? |
André Schreiber, Stephan Ludwig |
| 28 |
[GO] |
2025―Jan―30 |
Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLpro detected in the SCORPIO-SR phase 3 trial |
Takeki Uehara, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Takumi Imamura, Hiroki Sakaguchi, Akimasa Fukushi, Yosuke Takeda, Keiko Baba, Haruaki Nobori, Tadashi Miyamoto, Shuhei Arita, Reiko Dodo, Alice Shimba, Keita Fukao, Takao Shishido, Yuko Tsuge, Hiroshi Mukae |
| 29 |
[GO] |
2025―Jan―27 |
Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients |
Qian Wu, Hairuo Wu, Yabin Hu, Xingyu Zheng, Fangfang Chang, Yongchen Liu, Zhendong Pan, Qijie Wang, Fei Tang, Jun Qian, Yuezhou Li, Bin Huang, Keqiu Chen, Juan Xu, You Wang, Xiangping Xie, Ping Zhao, Xu Wu, Xiaowang Qu, Yi-Ping Li |
| 30 |
[GO] |
2025―Jan―17 |
IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility |
Mengxin Xu, Zhaoyong Zhang, Yuzhu Sun, Haoting Mai, Siqi Liu, Shuning Liu, Kexin Lv, Feiyang Yu, Yuanyuan Wang, Xinyu Yue, Jiayi Zhang, Xiaoyu Cai, Ruixin Zhao, Hongjie Lu, Lin Liu, Huanle Luo, Haiyan Zhao, Yanqun Wang, Peng Gong, Shoudeng Chen, Xuping Jing, Jincun Zhao, Yao-Qing Chen |
| 31 |
[GO] |
2024―Dec―15 |
Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity |
Binbin Wang, Hongjie Xia, Bi-Hung Peng, Eun-Jin Choi, Bing Tian, Xuping Xie, Shinji Makino, Xiaoyong Bao, Pei-Yong Shi, Vineet Menachery, Tian Wang |
| 32 |
[GO] |
2024―Nov―20 |
Biological Characterization of AB-343, a Novel and Potent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity |
Kayleigh R. McGovern-Gooch, Nagraj Mani, Dimitar Gotchev, Andrzej Ardzinski, Rose Kowalski, Muhammad Sheraz, Holly M. Micolochick Steuer, Breanna Tercero, Xiaohe Wang, Adam Wasserman, Chia-yi Chen, Konstanze von König, Klaus Maskos, Archna Prasad, Michael Blaesse, Andreas Bergmann, Debora L. Konz Makino, Kristi Y. Fan, Steven G. Kultgen, Aaron Lindstrom, Duyan Nguyen, Marvin Vega, Xu Wang, Nicole Bracci, Susan R. Weiss, Andrew G. Cole, Angela M. Lam, Andrea Cuconati, Michael J. Sofia |
| 33 |
[GO] |
2024―Nov―19 |
X-206 exhibits broad-spectrum anti-β-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates |
Jiei Sasaki, Akihiko Sato, Michihito Sasaki, Iori Okabe, Kota Kodama, Satoko Otsuguro, Kosuke Yasuda, Hirotatsu Kojima, Yasuko Orba, Hirofumi Sawa, Katsumi Maenaka, Yusuke Yanagi, Takao Hashiguchi |
| 34 |
[GO] |
2024―Nov―05 |
The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase |
Bhawna Sama, Barbara Selisko, Camille Falcou, Véronique Fattorini, Géraldine Piorkowski, Franck Touret, Kim Donckers, Johan Neyts, Dirk Jochmans, Ashleigh Shannon, Bruno Coutard, Bruno Canard |
| 35 |
[GO] |
2024―Oct―30 |
Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model |
Masaaki Nakashima, Haruaki Nobori, Takayuki Kuroda, Alice Shimba, Satoshi Miyagawa, Akane Hayashi, Kazumi Matsumoto, Mei Yoshida, Kaoru Baba, Teruhisa Kato, Keita Fukao |
| 36 |
[GO] |
2024―Oct―17 |
Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon System |
Chieh-Wen Lo, Omri Kariv, Chenzhou Hao, Karen Anbro Gammeltoft, Jens Bukh, Judith Gottwein, Michael Westberg, Michael Z. Lin, Shirit Einav |
| 37 |
[GO] |
2024―Sep―25 |
Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses |
Demi van der Horst, Madalina E. Carter-Timofte, Adeline Danneels, Leandro Silva da Costa, Naziia Kurmasheva, Anne L. Thielke, Anne Louise Hansen, Vladimir Chorošajev, Christian K. Holm, Sandrine Belouzard, Ivan de Weber, Cedric Beny, David Olagnier |
| 38 |
[GO] |
2024―Sep―16 |
Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis |
Priya Kumar, Xiaoxiao Zhang, Rahul Shaha, Maik Kschischo, Matthias Dobbelstein |
| 39 |
[GO] |
2024―Sep―03 |
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model. |
Thuc Nguyen Dan Do, Rana Abdelnabi, Bernadett Boda, Samuel Constant, Johan Neyts, Dirk Jochmans |
| 40 |
[GO] |
2024―Aug―23 |
Coronavirus Nucleocapsid-based Vaccine Provides Partial Protection against Hetero-species Coronavirus in Murine Models |
Pureum Lee, Jihee Kim, Hanseul Oh, Chang-Ung Kim, Ahn Young Jeong, Moo-Seung Lee, Min Seong Jang, Jung Joo Hong, Jung-Eun Park, Doo-Jin Kim |
| 41 |
[GO] |
2024―Aug―16 |
Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV Pandemic Response Box |
Michael O. Okpara, Frederick Weaver, Adrian Whitehouse, Clinton G.L. Veale, Adrienne L. Edkins |
| 42 |
[GO] |
2024―Aug―13 |
Characterization of therapeutic antibodies efficacy against multiple SARS-CoV-2 variants in the hamster model |
Yu Cong, Saurabh Dixit, Donna L. Perry, Louis M. Huzella, Erin Kollins, Russell Byrum, Scott M. Anthony, David Drawbaugh, Sanae Lembirik, Elena Postnikova, Brett Eaton, Michael Murphy, Gregory Kocher, Kyra Hadley, Anthony E. Marketon, Rebecca M. Bernbaum, Amanda M.W. Hischak, Randy Hart, Nick Vaughan, Jiro Wada, Jing Qin, Marisa C. St.Claire, Connie S. Schmaljohn, Michael R. Holbrook |
| 43 |
[GO] |
2024―Aug―06 |
Amidino-Rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis |
Patrick T. Keiser, Wenhan Zhang, Michael Ricca, Alan Wacquiez, Autumn Grimins, Regina Cencic, J.J. Patten, Pranav Shah, Elias Padilha, John H. Connor, Jerry Pelletier, Shawn M. Lyons, Mohsan Saeed, Lauren E. Brown, John A. Porco, Robert A. Davey |
| 44 |
[GO] |
2024―Jul―26 |
Nirmatrelvir and Molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 Omicron subvariants |
Romel Rosales, Briana L. McGovern, M. Luis Rodriguez, Rocio Leiva-Rebollo, Randy Diaz-Tapia, Jared Benjamin, Devendra K. Rai, Rhonda D. Cardin, Annaliesa S. Anderson, Emilia Mia Sordillo, Harm van Bakel, Viviana Simon, Adolfo García-Sastre, Kris M. White, Hala Alshammary, R. Banu, K. Farrugia, Ana Silvia Gonzalez-Reiche, A. Paniz-Mondolfi, J. Polanco |
| 45 |
[GO] |
2024―Jul―23 |
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system |
Stefanie Rauch, Francesco Costacurta, Helge Schöppe, Ju-Yi Peng, David Bante, Ela Emilie Erisoez, Bernhard Sprenger, Xi He, Seyed Arad Moghadasi, Laura Krismer, Anna Sauerwein, Anne Heberle, Toni Rabensteiner, Dai Wang, Andreas Naschberger, Theresia Dunzendorfer-Matt, Teresa Kaserer, Dorothee von Laer, Emmanuel Heilmann |
| 46 |
[GO] |
2024―Jul―14 |
A mimetic peptide of ACE2 protects against SARS-CoV-2 infection and decreases pulmonary inflammation related to COVID-19 |
Ernna H. Oliveira, Ana C. Monteleone-Cassiano, Lucas Tavares, Jadson C. Santos, Thais M. Lima, Giovanni F. Gomes, Pedro P. Tanaka, Cintia J. Monteiro, Matheus Munuera, Sabrina S. Batah, Alexandre T. Fabro, Vitor M. Faça, Ana P. Masson, Eduardo A. Donadi, Mariangela Dametto, Rodrigo Bonacin, Ronaldo B. Martins, Eurico Arruda Neto, Luis Lamberti P. daSilva, Thiago M. Cunha, Geraldo A. Passos |
| 47 |
[GO] |
2024―Jul―06 |
Prevention of Post COVID-19 Condition by Early Treatment with Ensitrelvir in the Phase 3 SCORPIO-SR Trial |
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Akimasa Fukushi, Takumi Imamura, Hiroki Sakaguchi, Takuhiro Sonoyama, Takao Sanaki, Genki Ichihashi, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae |
| 48 |
[GO] |
2024―Jul―02 |
Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant. |
Jia Ji, Taoming Tang, Miaojin Zhu, Zhigang Wu, Jiale Zhang, Danrong Shi, Lingwei Zhu, Xiaodi Zhang, Xiangyun Lu, Lei Chen, Hangping Yao |
| 49 |
[GO] |
2024―Jun―28 |
Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy |
Nathalia Williams, Filo Silva, Mirco Schmolke |
| 50 |
[GO] |
2024―Jun―26 |
Molecules targeting a novel homotrimer cavity of Spike protein attenuate replication of SARS-CoV-2 |
Alison Daniels, Monikaben Padariya, Sarah Fletcher, Kathryn Ball, Ashita Singh, Neil Carragher, Ted Hupp, Christine Tait-Burkard, Umesh Kalathiya |
| 51 |
[GO] |
2024―Jun―24 |
Targeting sgRNA N secondary structure as a way of inhibiting SARS-CoV-2 replication |
Agnieszka Baliga-Gil, Marta Soszynska-Jozwiak, Agnieszka Ruszkowska, Izabela Szczesniak, Ryszard Kierzek, Maria Ciechanowska, Magdalena Trybus, Paulina Jackowiak, Jake M. Peterson, Walter N. Moss, Elzbieta Kierzek |
| 52 |
[GO] |
2024―Jun―22 |
Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-CoV-2 PLpro |
Xin Liu, Miao Zheng, Hongqing Zhang, Bo Feng, Jiaqi Li, Yanan Zhang, Ji Zhang, Na Zhao, Chaoqiang Li, Ning Song, Bin Song, Dongyuan Yang, Jin Chen, Ao Qi, Linxiang Zhao, Cheng Luo, Yi Zang, Hong Liu, Jia Li, Bo Zhang, Yu Zhou, Jie Zheng |
| 53 |
[GO] |
2024―Jun―18 |
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination |
Thayne H. Dickey, Nichole D. Salinas, Palak Patel, Sachy Orr-Gonzalez, Tarik Ouahes, Holly McAleese, Brandi L. Richardson, Myesha Singleton, Michael Murphy, Brett Eaton, Jennifer L. Kwan, Michael R. Holbrook, Lynn E. Lambert, Niraj H. Tolia |
| 54 |
[GO] |
2024―May―31 |
The coronavirus nsp15 endoribonuclease: a puzzling protein and pertinent antiviral drug target |
Benjamin Van Loy, Annelies Stevaert, Lieve Naesens |
| 55 |
[GO] |
2024―May―29 |
Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants |
Uyen Nguyen Phuong Le, Yu-Jen Chang, Chih-Hao Lu, Yeh Chen, Wen-Chi Su, Shao-Ting Chao, Lia A. Baltina, Svetlana F. Petrova, Sin-Rong Li, Mien-Chie Hung, Michael M.C. Lai, Lidia A. Baltina, Cheng-Wen Lin |
| 56 |
[GO] |
2024―May―21 |
Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2 |
Yucai Liang, Weiling Xiao, Yuan Peng, Shengshuo Zhang, Jinhua Dong, Jun Zhao, Yuhui Wang, Mengtao Zhang, Zhijun Liu, Bowen Yu |
| 57 |
[GO] |
2024―May―11 |
Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2 |
Jingbo Huang, Weiqi Wang, Hailun Li, Yujie Bai, Yumeng Song, Cuicui Jiao, Hongli Jin, Pei Huang, Haili Zhang, Xianzhu Xia, Feihu Yan, Yuanyuan Li, Hualei Wang |
| 58 |
[GO] |
2024―May―08 |
SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron Variant of SARS-CoV-2 |
Kabita Pandey, Arpan Acharya, Dhananjaya Pal, Prashant Jain, Kamal Singh, Donald L. Durden, Tatiana G. Kutateladze, Aniruddha J. Deshpande, Siddappa N. Byrareddy |
| 59 |
[GO] |
2024―May―07 |
Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond |
Clarisse Salgado-Benvindo, Ali Tas, Jessika C. Zevenhoven-Dobbe, Yvonne van der Meer, Igor A. Sidorov, Anouk A. Leijs, Patrick Wanningen, Anne T. Gelderloos, Puck B. van Kasteren, Eric J. Snijder, Martijn J. van Hemert |
| 60 |
[GO] |
2024―Apr―29 |
Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD |
Xiaochun Liu, Yanqing Wang, Lishan Sun, Guokai Xiao, Ning Hou, Jin Chen, Wei Wang, Ximing Xu, Yuchao Gu |
| 61 |
[GO] |
2024―Apr―25 |
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19? |
Rohan Ameratunga, Anthony Jordan, Klaus Lehnert, Euphemia Leung, Emily R. Mears, Russell Snell, Richard Steele, See-Tarn Woon |
| 62 |
[GO] |
2024―Apr―09 |
Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses |
Beatrice Tolksdorf, Julian Heinze, Daniela Niemeyer, Viola Röhrs, Johanna Berg, Christian Drosten, Jens Kurreck |
| 63 |
[GO] |
2024―Mar―28 |
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses |
Andrei E. Siniavin, Vladimir A. Gushchin, Natal'ya S. Shastina, Elizaveta S. Darnotuk, Sergey I. Luyksaar, Leonid I. Russu, Anna M. Inshakova, Elena V. Shidlovskaya, Daria V. Vasina, Nadezhda A. Kuznetsova, Daria M. Savina, Ilya D. Zorkov, Inna V. Dolzhikova, Anna B. Sheremet, Denis Y. Logunov, Nailya A. Zigangirova, Alexander L. Gintsburg |
| 64 |
[GO] |
2024―Mar―28 |
Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors |
Kaustav Khatua, Yugendar R. Alugubelli, Kai S. Yang, Veerabhadra R. Vulupala, Lauren R. Blankenship, Demonta Coleman, Sandeep Atla, Sankar P. Chaki, Zhi Zachary Geng, Xinyu R. Ma, Jing Xiao, Peng-Hsun Chen, Chia-Chuan D. Cho, Shivangi Sharma, Erol C. Vatansever, Yuying Ma, Ge Yu, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu |
| 65 |
[GO] |
2024―Mar―14 |
A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication |
Christopher Moon, Eleanor Porges, Adam Roberts, Joanna Bacon |
| 66 |
[GO] |
2024―Mar―13 |
Caffeic acid phenethyl ester: An effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus |
Zhanding Cui, Jing Zhang, Jinlong Wang, Jinlong Liu, Pu Sun, Jiaoyang Li, Guoxiu Li, Ying Sun, Juanbin Ying, Kun Li, Zhixun Zhao, Hong Yuan, Xingwen Bai, Xueqing Ma, Pinghua Li, Yuanfang Fu, Huifang Bao, Dong Li, Qiang Zhang, Zaixin Liu, Yimei Cao, Zengjun Lu |
| 67 |
[GO] |
2024―Mar―05 |
Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A |
Maja Klevanski, Heeyoung Kim, Mike Heilemann, Thomas Kuner, Ralf Bartenschlager |
| 68 |
[GO] |
2024―Mar―05 |
SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential |
Magdalena Bandyszewska, Magdalena Ambrożek-Latecka, Grażyna Hoser, Małgorzata Grzanka, Franziska Hornung, Stefanie Deinhardt-Emmer, Tomasz Skirecki |
| 69 |
[GO] |
2024―Mar―05 |
A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2 |
Weiqi Wang, Shen Wang, Xianyong Meng, Yongkun Zhao, Nan Li, Tiecheng Wang, Na Feng, Feihu Yan, Xianzhu Xia |
| 70 |
[GO] |
2024―Mar―02 |
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance |
André Schreiber, Franziska Rodner, Nicole Oberberg, Darisuren Anhlan, Stefan Bletz, Alexander Mellmann, Oliver Planz, Stephan Ludwig |
| 71 |
[GO] |
2024―Feb―28 |
Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2 |
Haruaki Nobori, Keiko Baba, Takayuki Kuroda, Kaoru Baba, Kazumi Matsumoto, Shinpei Yoshida, Ryosuke Watari, Yuki Tachibana, Teruhisa Kato, Keita Fukao |
| 72 |
[GO] |
2024―Feb―24 |
Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3 C L protease as a potential candidate against SARS-cov-2 infection |
Hongtao Li, Meng Sun, Fuzhi Lei, Jinfeng Liu, Xixiang Chen, Yaqi Li, Ying Wang, Jiani Lu, Danmei Yu, Yueqiu Gao, Jianrong Xu, Hongzhuan Chen, Man Li, Zhigang Yi, Xiao He, Lili Chen |
| 73 |
[GO] |
2024―Feb―20 |
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses |
Maria Giulia Bigotti, Katja Klein, Esther S. Gan, Maria Anastasina, Simon Andersson, Olli Vapalahti, Pekka Katajisto, Maximilian Erdmann, Andrew D. Davidson, Sarah J. Butcher, Ian Collinson, Eng Eong Ooi, Giuseppe Balistreri, Andrea Brancaccio, Yohei Yamauchi |
| 74 |
[GO] |
2024―Feb―02 |
An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses |
Yuanhong Wang, Yun Liu, Junna Wang, Miao Zhang, Xiaoying Deng, Junhan Song, Jie Zhu, Lingxue Yu, Guoxin Li, Guangqing Liu |
| 75 |
[GO] |
2024―Feb―01 |
Therapeutic antibodies and alternative formats against SARS-CoV-2 |
Rahel R. Winiger, Laurent Perez |
| 76 |
[GO] |
2024―Jan―24 |
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome |
Mariia S. Bogacheva, Suvi Kuivanen, Swapnil Potdar, Antti Hassinen, Sini Huuskonen, Ina Pöhner, Tamara J. Luck, Laura Turunen, Michaela Feodoroff, Leonora Szirovicza, Kirsi Savijoki, Jani Saarela, Päivi Tammela, Lassi Paavolainen, Antti Poso, Markku Varjosalo, Olli Kallioniemi, Vilja Pietiäinen, Olli Vapalahti |
| 77 |
[GO] |
2024―Jan―24 |
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains |
Hawa Sophia Bouzidi, Jean-Sélim Driouich, Raphaëlle Klitting, Ornéllie Bernadin, Géraldine Piorkowski, Rayane Amaral, Laurent Fraisse, Charles E. Mowbray, Ivan Scandale, Fanny Escudié, Eric Chatelain, Xavier de Lamballerie, Antoine Nougairède, Franck Touret |
| 78 |
[GO] |
2024―Jan―19 |
An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. |
Adi Idris, Aroon Supramaniam, Yaman Tayyar, Gabrielle Kelly, NigelA.J. McMillan, Kevin V. Morris |
| 79 |
[GO] |
2024―Jan―09 |
TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences |
Tea Govednik, Duško Lainšček, Urška Kuhar, Marva Lachish, Sandra Janežič, Malan Štrbenc, Uroš Krapež, Roman Jerala, Daphne Atlas, Mateja Manček-Keber |
| 80 |
[GO] |
2023―Dec―27 |
A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects |
Jordi Doijen, Inha Heo, Koen Temmerman, Peter Vermeulen, Annick Diels, Steffen Jaensch, Mark Burcin, Nick Van den Broeck, Valerie Raeymaekers, Joren Peremans, Katrien Konings, Maxime Clement, Danielle Peeters, Marnix Van Loock, Anil Koul, Christophe Buyck, Michiel Van Gool, Ellen Van Damme |
| 81 |
[GO] |
2023―Dec―27 |
Deubiquitinase USP39 promotes SARS-CoV-2 replication by deubiquitinating and stabilizing the envelope protein |
Xiang Chen, Li Tian, Linran Zhang, Wenying Gao, Miao Yu, Zhaolong Li, Wenyan Zhang |
| 82 |
[GO] |
2023―Dec―07 |
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters |
Metin Aksu, Priya Kumar, Thomas Güttler, Waltraud Taxer, Kathrin Gregor, Bianka Mußil, Oleh Rymarenko, Kim M. Stegmann, Antje Dickmanns, Sabrina Gerber, Wencke Reineking, Claudia Schulz, Timo Henneck, Ahmed Mohamed, Gerhard Pohlmann, Mehmet Ramazanoglu, Kemal Mese, Uwe Groß, Tamar Ben-Yedidia, Oded Ovadia, Dalit Weinstein Fischer, Merav Kamensky, Amir Reichman, Wolfgang Baumgärtner, Maren von Köckritz-Blickwede, Matthias Dobbelstein, Dirk Görlich |
| 83 |
[GO] |
2023―Dec―05 |
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis |
Meital Zur, Thalia Peselev, Stav Yanko, Victoria Rotshild, Ilan Matok |
| 84 |
[GO] |
2023―Nov―30 |
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro |
Lara Gallucci, James Bazire, Andrew D. Davidson, Iart Luca Shytaj |
| 85 |
[GO] |
2023―Nov―28 |
Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters |
Shen Wang, Huan Cui, Cheng Zhang, Wujian Li, Weiqi Wang, Wenwen He, Na Feng, Yongkun Zhao, Tiecheng Wang, Xiaoqing Tang, Feihu Yan, Xianzhu Xia |
| 86 |
[GO] |
2023―Nov―24 |
A phenothiazine urea derivative broadly inhibits coronavirus replication via viral protease inhibition |
Katrina Forrestall, Eric S. Pringle, Dane Sands, Brett A. Duguay, Brett Farewell, Tekeleselassie Woldemariam, Darryl Falzarano, Ian Pottie, Craig McCormick, Sultan Darvesh |
| 87 |
[GO] |
2023―Nov―21 |
Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection |
Alberto Gómez-Carballa, Guillermo Albericio, Julián Montoto-Louzao, Patricia Pérez, David Astorgano, Irene Rivero-Calle, Federico Martinón-Torres, Mariano Esteban, Antonio Salas, Juan García-Arriaza |
| 88 |
[GO] |
2023―Nov―19 |
Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses |
Chia-Ying Wu, Yung-Chieh Tseng, Shao-En Kao, Li-Yang Wu, Jen-Tzu Hou, Yu-Chih Yang, Pei-Wen Hsiao, Juine-Ruey Chen |
| 89 |
[GO] |
2023―Nov―19 |
Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization |
Qiu-Yan Zhang, Hong-Qing Zhang, Ya-Nan Zhang, Zhe-Rui Zhang, Xiao-Dan Li, Meng-Chan Hao, Yang Zhang, Jia-Qi Li, Yan-Yan Hu, Xiao-Ling Chen, Jing Wang, Yu-Jia Shi, Cheng-Lin Deng, Jian-Jun Chen, Han-Qing Ye, Bo Zhang |
| 90 |
[GO] |
2023―Nov―08 |
Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry |
Srikanth Sadhu, Jyotsna Dandotiya, Rajdeep Dalal, Ritika Khatri, Anna Z. Mykytyn, Aashima Batra, Manpreet Kaur, Rucha Chandwaskar, Virendra Singh, Aarzoo Kamboj, Mitul Srivastava, Shailendra Mani, Shailendra Asthana, Sweety Samal, Zaigham Abbas Rizvi, Deepak B. Salunke, Bart L. Haagmans, Amit Awasthi |
| 91 |
[GO] |
2023―Nov―08 |
Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit |
He-Chin Hsieh, Chung-Chu Chen, Pin-Han Chou, Wen-Chun Liu, Suh-Chin Wu |
| 92 |
[GO] |
2023―Nov―08 |
A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants |
Dong-Gun Kim, Uijin Kim, In Ho Park, Bumhan Ryu, Youngki Yoo, Jeong Seok Cha, Ga-Yeon Yoon, Sung-Hee Kim, Heeju Oh, Jun-Young Seo, Ki Taek Nam, Je Kyung Seong, Jeon-Soo Shin, Hyun-Soo Cho, Hak-Sung Kim |
| 93 |
[GO] |
2023―Nov―07 |
Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization |
Wen-Chi Su, Zan-Yu Chen, Young-Sheng Chang, King-Song Jeng, Uyen Nguyen Phuong Le, Yu-Chi Chou, Li-Lan Kuo, Ivonne Melano, Wei-Jan Wang, Ying-Chyi Song, Sin-Rong Li, Mien-Chie Hung, Michael M.C. Lai, Cheng-Wen Lin |
| 94 |
[GO] |
2023―Oct―18 |
Synthesis, evaluation, and mechanism of 1-(4-(arylethylenylcarbonyl)phenyl)-4-carboxy-2-pyrrolidinones as potent reversible SARS-CoV-2 entry inhibitors |
Srinivasa Rao Palla, Chen-Wei Li, Tai-Ling Chao, Hoi-Ling Vienn Lo, Liu Jia-Jin, Max Yu-Chen Pan, Yu-Ting Chiu, Wen-Chin Lin, Chih-Wei Hu, Chuen-Mi Yang, Yi-Ying Chen, Jun-Tung Fang, Sheng-Wei Lin, Yi-Tzu Lin, Hsiao-Ching Lin, Chih-Jung Kuo, Lily Hui-Ching Wang, Sui-Yuan Chang, Po-Huang Liang |
| 95 |
[GO] |
2023―Oct―18 |
ASK1 inhibitors are potential pan-antiviral drugs, which dampen replication of diverse viruses including SARS-CoV2 |
Wael L. Demian, Rajesh Abraham Jacob, Olga Cormier, Aisha Nazli, Matthew Melki, Akarin Asavajaru, Kaushal Baid, Ali Zhang, Matthew S. Miller, Charu Kaushic, Arinjay Banerjee, Karen Mossman |
| 96 |
[GO] |
2023―Oct―06 |
Induction of antiviral gene expression by cyclosporine a, but not inhibition of cyclophilin a or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line |
John E. Mamatis, Carla E. Gallardo-Flores, Ujjwal Sangwan, Trinity H. Tooley, Taylor Walsh, Che C. Colpitts |
| 97 |
[GO] |
2023―Sep―28 |
Corrigendum to ’ Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase’ [Antiviral Research 218 (2023) 105716-105728/ doi: 10.1016/j.antiviral.2023.105716] |
Ryan P. Bennett, Yasemin Yoluç, Jason D. Salter, Alexander Ripp, Henning J. Jessen, Stefanie M. Kaiser, Harold C. Smith |
| 98 |
[GO] |
2023―Sep―09 |
Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase |
Ryan P. Bennett, Yasemin Yoluç, Jason D. Salter, Alexander Ripp, Henning J. Jessen, Stefanie M. Kaiser, Harold C. Smith |
| 99 |
[GO] |
2023―Aug―09 |
Diketo acid inhibitors of nsp13 of SARS-CoV-2 block viral replication |
Angela Corona, Valentina Noemi Madia, Riccardo De Santis, Candida Manelfi, Roberta Emmolo, Davide Ialongo, Elisa Patacchini, Antonella Messore, Donatella Amatore, Giovanni Faggioni, Marco Artico, Daniela Iaconis, Carmine Talarico, Roberto Di Santo, Florigio Lista, Roberta Costi, Enzo Tramontano |
| 100 |
[GO] |
2023―Aug―09 |
PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding |
Evelien Vanderlinden, Arnaud Boonen, Sam Noppen, Geert Schoofs, Maya Imbrechts, Nick Geukens, Robert Snoeck, Annelies Stevaert, Lieve Naesens, Graciela Andrei, Dominique Schols |
| 101 |
[GO] |
2023―Jul―20 |
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2 |
Ellen Bowden-Reid, Scott Ledger, Yuan Zhang, Francesca Di Giallonardo, Anupriya Aggarwal, Alberto Ospina Stella, Anouschka Akerman, Vanessa Milogiannakis, Gregory Walker, William Rawlinson, Stuart Turville, Anthony D. Kelleher, Chantelle Ahlenstiel |
| 102 |
[GO] |
2023―Jul―20 |
Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response |
Łukasz Suprewicz, Artur Szczepański, Marzena Lenart, Ewelina Piktel, Krzysztof Fiedoruk, Emilia Barreto-Duran, Anna Kula-Pacurar, Paul B. Savage, Aleksandra Milewska, Robert Bucki, Krzysztof Pyrć |
| 103 |
[GO] |
2023―Jul―17 |
Seasonal coronavirus infections trigger NLRP3 inflammasome activation in macrophages but is therapeutically targetable |
Yang Li, Yining Wang, Yunlong Li, Annemarie C. de Vries, Pengfei Li, Maikel P. Peppelenbosch, Qiuwei Pan |
| 104 |
[GO] |
2023―Jul―13 |
Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors |
Emi Takashita, Seiichiro Fujisaki, Hiroko Morita, Shiho Nagata, Hideka Miura, Mami Nagashima, Shinji Watanabe, Makoto Takeda, Yoshihiro Kawaoka, Hideki Hasegawa |
| 105 |
[GO] |
2023―Jul―11 |
Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses |
Ju Hwan Jeong, Jang-Hoon Choi, Beom Kyu Kim, Seong Cheol Min, Santosh Chokkakula, Sol Oh, Ji-Hyun Park, Sang-Mu Shim, Eung-Gook Kim, Young Ki Choi, Joo-Yeon Lee, Yun Hee Baek, Min-Suk Song |
| 106 |
[GO] |
2023―Jul―08 |
Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection |
Yifei Feng, Yan Yang, Shuting Zou, Shuqi Qiu, Hao Yang, Yi Hu, Guifen Lin, Xingang Yao, Shuwen Liu, Min Zou |
| 107 |
[GO] |
2023―Jun―25 |
Paxlovid for hospitalized COVID-19 patients with chronic kidney disease |
Hong Cai, Jiayi Yan, Shang Liu, Ping Li, Li Ding, Yaping Zhan, Jiayue Lu, Zhenyuan Li, Mingli Zhu, Yuan Gao, XingRong Gong, Haiqun Ban, Leyi Gu, Weibin Zhou, Jieying Wang, Shan Mou |
| 108 |
[GO] |
2023―Jun―23 |
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection |
Rafaela Milan Bonotto, Ana Mitrović, Izidor Sosič, Pamela Martinez-Orellana, Federica Dattola, Stanislav Gobec, Janko Kos, Alessandro Marcello |
| 109 |
[GO] |
2023―Jun―15 |
Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2 |
Hi Eun Jung, Keun Bon Ku, Byeong Hoon Kang, Jang Hyun Park, Hyeon Cheol Kim, Kyun-Do Kim, Heung Kyu Lee |
| 110 |
[GO] |
2023―Jun―15 |
Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV |
Yu-Jen Chang, Uyen Nguyen Phuong Le, Jia-Jun Liu, Sin-Rong Li, Shao-Ting Chao, Hsueh-Chou Lai, Yu-Feng Lin, Kai-Cheng Hsu, Chih-Hao Lu, Cheng-Wen Lin |
| 111 |
[GO] |
2023―May―18 |
SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril |
Xiaohan Huang, Wenxia Fan, Jing Sun, Jiaqing Yang, Yanjun Zhang, Qian Wang, Pingchao Li, Yudi Zhang, Shengnan Zhang, Heying Li, Jianhua Wang, Liqiang Feng, Jincun Zhao, Ling Chen, Qu Linbing |
| 112 |
[GO] |
2023―Apr―20 |
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants |
Junhyung Cho, Younmin Shin, Jeong-Sun Yang, Jun Won Kim, Kyung-Chang Kim, Joo-Yeon Lee |
| 113 |
[GO] |
2023―Apr―18 |
Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2 |
Yihua Li, Kun Wang, Hongmin Sun, Shuo Wu, Huiqiang Wang, Yuanyuan Shi, Xingxing Li, Haiyan Yan, Ge Yang, Mengyuan Wu, Yihong Li, Xiaotian Ding, Shuyi Si, Jiandong Jiang, Yu Du, Yuhuan Li, Bin Hong |
| 114 |
[GO] |
2023―Apr―15 |
Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models |
Yu Cong, Ji Hyun Lee, Donna L. Perry, Kurt Cooper, Hui Wang, Saurabh Dixit, David X. Liu, Irwin M. Feuerstein, Jeffrey Solomon, Christopher Bartos, Jurgen Seidel, Dima A. Hammoud, Ricky Adams, Scott M. Anthony, Janie Liang, Nicolette Schuko, Rong Li, Yanan Liu, Zhongde Wang, E. Bart Tarbet, Amanda M.W. Hischak, Randy Hart, Nejra Isic, Tracey Burdette, David Drawbaugh, Louis M. Huzella, Russell Byrum, Danny Ragland, Marisa C. St Claire, Jiro Wada, Jonathan R. Kurtz, Lisa E. Hensley, Connie S. Schmaljohn, Michael R. Holbrook, Reed F. Johnson |
| 115 |
[GO] |
2023―Mar―31 |
The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2 |
Cody Bills, Xuping Xie, Pei-Yong Shi |
| 116 |
[GO] |
2023―Mar―30 |
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters |
Yu Cong, Eric M. Mucker, Donna L. Perry, Saurabh Dixit, Erin Kollins, Russ Byrum, Louis Huzella, Robert Kim, Mathew Josleyn, Steven Kwilas, Christopher Stefan, Charles J. Shoemaker, Jeff Koehler, Susan Coyne, Korey Delp, Janie Liang, David Drawbaugh, Amanda Hischak, Randy Hart, Elena Postnikova, Nick Vaughan, Jason Asher, Marisa St Claire, Jarod Hanson, Connie Schmaljohn, Ann E. Eakin, Jay W. Hooper, Michael R. Holbrook |
| 117 |
[GO] |
2023―Mar―28 |
Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2 |
Yujian Yang, Liu Cao, Ming Yan, Jun Zhou, Sidi Yang, Tiefeng Xu, Siyao Huang, Kun Li, Qifan Zhou, Guanguan Li, Yujun Zhu, Feng Cong, Hongmin Zhang, Deyin Guo, Yingjun Li, Xumu Zhang |
| 118 |
[GO] |
2023―Mar―26 |
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants |
Emiel Vanhulle, Jordi Doijen, Joren Stroobants, Becky Provinciael, Sam Noppen, Dominique Schols, Annelies Stevaert, Kurt Vermeire |
| 119 |
[GO] |
2023―Mar―20 |
SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model |
Rubens Prince dos Santos Alves, Ying-Ting Wang, Zbigniew Mikulski, Sara McArdle, Norazizah Shafee, Kristen M. Valentine, Robyn Miller, Shailendra Verma, Fernanda Ana Sosa Batiz, Erin Maule, Michael N. Nguyen, Julia Timis, Colin Mann, Michelle Zandonatti, Suzie Alarcon, Jenny Rowe, Mitchell Kronenberg, Daniela Weiskopf, Alessandro Sette, Kathryn Hastie, Erica Ollmann Saphire, Stephen Festin, Kenneth Kim, Sujan Shresta |
| 120 |
[GO] |
2023―Mar―05 |
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine |
Changrui Lu, Yuntao Zhang, Xiaohu Liu, Fujun Hou, Rujie Cai, Zhibin Yu, Fei Liu, Guohuan Yang, Jun Ding, Jiang Xu, Xianwu Hua, Xinhua Cheng, Xinping Pan, Lianxiao Liu, Kang Lin, Zejun Wang, Xinguo Li, Jia Lu, Qiu Zhang, Yuwei Li, Chunxia Hu, Huifen Fan, Xiaoke Liu, Hui Wang, Rui Jia, Fangjingwei Xu, Xuewei Wang, Hongwei Huang, Ronghua Zhao, Jing Li, Hang Cheng, William Jia, Xiaoming Yang |
| 121 |
[GO] |
2023―Mar―02 |
Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs |
Egor V. Shekunov, Polina D. Zlodeeva, Svetlana S. Efimova, Anna A. Muryleva, Vladimir V. Zarubaev, Alexander V. Slita, Olga S. Ostroumova |
| 122 |
[GO] |
2023―Mar―02 |
Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants |
Ji Woong Kim, Kyun Heo, Hyun Jung Kim, Youngki Yoo, Hyun-Soo Cho, Hui Jeong Jang, Ho-Young Lee, In Young Ko, Ju Rang Woo, Yea Bin Cho, Ji Hyun Lee, Ha Rim Yang, Ha Gyeong Shin, Hye Lim Choi, Kyusang Hwang, Sokho Kim, Hanseong Kim, Kwangrok Chun, Sukmook Lee |
| 123 |
[GO] |
2023―Mar―01 |
Pinosrtobin from plants and propolis against human coronavirus HCoV-OC43 by modulating host AHR/CYP1A1 pathway and lipid metabolism |
Liyun Zhao, Liyuan Yao, Rui Chen, Jiani He, Tingting Lin, Silin Qiu, Guohua Chen, Hongfeng Chen, Sheng-Xiang Qiu |
| 124 |
[GO] |
2023―Mar―01 |
Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides |
Yue Hu, Yuanmei Zhu, Yanying Yu, Nian Liu, Xiaohui Ju, Qiang Ding, Yuxian He |
| 125 |
[GO] |
2023―Feb―18 |
CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation |
Yingzi Xiao, Ying Yan, Le Chang, Huimin Ji, Huizhen Sun, Shi Song, Kaihao Feng, Abudulimutailipu Nuermaimaiti, Zhuoqun Lu, Lunan Wang |
| 126 |
[GO] |
2023―Feb―14 |
Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses |
Jiajing Li, Yining Wang, Kundan Solanki, Rajat Atre, Marla Lavrijsen, Qiuwei Pan, Mirza S. Baig, Pengfei Li |
| 127 |
[GO] |
2023―Feb―03 |
Nucleolin mediates SARS-CoV-2 replication and viral-induced apoptosis of host cells |
Vanessa F. Merino, Yu Yan, Alvaro A. Ordonez, C. Korin Bullen, Albert Lee, Harumi Saeki, Krishanu Ray, Tao Huang, Sanjay K. Jain, Martin G. Pomper |
| 128 |
[GO] |
2023―Jan―20 |
Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2 |
Yuanmei Zhu, Min Li, Nian Liu, Tong Wu, Xuelian Han, Guangyu Zhao, Yuxian He |
| 129 |
[GO] |
2022―Dec―29 |
“Flavivirus proteases: The viral Achilles heel to prevent future pandemics” |
Tadahisa Teramoto, Kyung H. Choi, Radhakrishnan Padmanabhan |
| 130 |
[GO] |
2022―Dec―27 |
Targeting SARS-CoV-2 and host cell receptor interactions |
Siew Pheng Lim |
| 131 |
[GO] |
2022―Dec―24 |
A new intracellular targeting motif in the cytoplasmic tail of the spike protein may act as a target to inhibit SARS-CoV-2 assembly |
Longbo Hu, Yongjie Tang, Lingling Mei, Mengdi Liang, Jinxian Huang, Xufei Wang, Liping Wu, Jiajing Jiang, Leyi Li, Fei Long, Jing Xiao, Long Tan, Shaohua Lu, Tao Peng |
| 132 |
[GO] |
2022―Dec―23 |
Influenza antivirals and their role in pandemic preparedness |
Jeremy C. Jones, Hui-Ling Yen, Peter Adams, Kimberly Armstrong, Elena A. Govorkova |
| 133 |
[GO] |
2022―Dec―22 |
Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2 |
Ashleigh Shannon, Bruno Canard |
| 134 |
[GO] |
2022―Dec―22 |
Reverse genetic systems of SARS-CoV-2 for antiviral research |
Chaitanya Kurhade, Xuping Xie, Pei-Yong Shi |
| 135 |
[GO] |
2022―Dec―21 |
Intranasal delivery of replicating mRNA encoding hACE2-targeting antibody against SARS-CoV-2 Omicron infection in the hamster |
Ya-Nan Zhang, Hong-Qing Zhang, Gui-Feng Wang, Zhe-Rui Zhang, Jia-Qi Li, Xiao-Ling Chen, Yan-Yan Hu, Xiang-Yue Zeng, Yu-Jia Shi, Jing Wang, Ying-Hua Li, Xiao-Dan Li, Chun-He Wang, Bing Zhu, Bo Zhang |
| 136 |
[GO] |
2022―Dec―21 |
Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery |
Winston Chiu, Joost Schepers, Thibault Francken, Laura Vangeel, Kayvan Abbasi, Dirk Jochmans, Steven De Jonghe, Hendrik Jan Thibaut, Volker Thiel, Johan Neyts, Manon Laporte, Pieter Leyssen |
| 137 |
[GO] |
2022―Dec―16 |
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model |
Dylan M. Johnson, Trevor Brasel, Shane Massey, Tania Garron, Michael Grimes, Jeanon Smith, Maricela Torres, Shannon Wallace, Alejandro Villasante-Tezanos, David W. Beasley, Jason E. Comer |
| 138 |
[GO] |
2022―Dec―05 |
Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1 |
Mei Hashizume, Ayako Takashima, Chikako Ono, Toru Okamoto, Masaharu Iwasaki |
| 139 |
[GO] |
2022―Dec―01 |
RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5ʹ-untranslated region |
Yongxuan Yao, Hao Sun, Yingshan Chen, Lingqian Tian, Dan Huang, Canyu Liu, Yuan Zhou, Yun Wang, Zhe Wen, Bo Yang, Xinwen Chen, Rongjuan Pei |
| 140 |
[GO] |
2022―Nov―23 |
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay |
Kwiwan Jeong, JuOae Chang, Sun-mi Park, Jinhee Kim, Sangeun Jeon, Dong Hwan Kim, Young-Eui Kim, Joo Chan Lee, Somyoung Im, Yejin Jo, Ji-Young Min, Hanbyeul Lee, Minjoo Yeom, Sang-Hyuk Seok, Da In On, Hyuna Noh, Jun-Won Yun, Jun Won Park, Daesub Song, Je Kyung Seong, Kyung-Chang Kim, Joo-Yeon Lee, Hyun-Ju Park, Seungtaek Kim, Tae-gyu Nam, Wonsik Lee |
| 141 |
[GO] |
2022―Nov―21 |
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier |
Aileen Faist, Sebastian Schloer, Angeles Mecate-Zambrano, Josua Janowski, André Schreiber, Yvonne Boergeling, Beate C.G. Conrad, Sriram Kumar, Leonie Toebben, Klaus Schughart, Morris Baumgardt, Mirjana Kessler, Katja Hoenzke, Andreas Hocke, Marcel Trautmann, Wolfgang Hartmann, Hiroki Kato, Ursula Rescher, Anmari Christersson, Joachim Kuehn, Alexander Mellmann, Thorsten Wolff, Philip Kuempers, Alexandros Rovas, Rainer Wiewrodt, Karsten Wiebe, Peter Barth, Stephan Ludwig, Linda Brunotte |
| 142 |
[GO] |
2022―Nov―17 |
In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection |
Xianfeng Hui, Xiao Yu, Kun Huang, Ting Xu, Lei Cao, Yufei Zhang, Lianzhong Zhao, Ya Zhao, Changjie Lv, sheng Feng, Yongzhong Jiang, Linlin Liu, Meilin Jin |
| 143 |
[GO] |
2022―Nov―03 |
Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404 |
Montserrat Fàbrega-Ferrer, Alejandra Herrera-Morandé, Sara Muriel-Goñi, Julia Pérez-Saavedra, Paula Bueno, Victoria Castro, Urtzi Garaigorta, Pablo Gastaminza, Miquel Coll |
| 144 |
[GO] |
2022―Oct―31 |
Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus |
Tianyi Zhang, Shuaikun Su, Valerie Altouma, Xingliang Zhu, Yutong Xue, Weiping Shen, Brian Wilgenburg, Weidong Wang |
| 145 |
[GO] |
2022―Oct―30 |
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2 |
Weijuan Shang, Wenhao Dai, Cheng Yao, Ling Xu, Xiangming Tao, Haixia Su, Jian Li, Xiong Xie, Yechun Xu, Min Hu, Dong Xie, Hualiang Jiang, Leike Zhang, Hong Liu |
| 146 |
[GO] |
2022―Oct―29 |
Geneticin shows selective antiviral activity against SARS-CoV-2 by interfering with programmed -1 ribosomal frameshifting |
Carmine Varricchio, Gregory Mathez, Trestan Pillonel, Claire Bertelli, Laurent Kaiser, Caroline Tapparel, Andrea Brancale, Valeria Cagno |
| 147 |
[GO] |
2022―Oct―17 |
Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides |
Yuanmei Zhu, Yue Hu, Nian Liu, Huihui Chong, Yuxian He |
| 148 |
[GO] |
2022―Oct―15 |
Astersaponin I from Aster koraiensis is a natural viral fusion blocker that inhibit the infection of SARS-CoV-2 variants and syncytium formation |
Tai Young Kim, Ji-Young Kim, Hak Cheol Kwon, Sangeun Jeon, Sol ji Lee, Haejin Jung, Seungtaek Kim, Dae Sik Jang, C Justin Lee |
| 149 |
[GO] |
2022―Oct―06 |
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice |
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, Beom Kyu Kim, Won-Suk Choi, Sol Oh, Yu Soo Yun, Da Hyeon Kang, Ok-Jun Lee, Eung-Gook Kim, Jang-Hoon Choi, Joo-Yeon Lee, Young Ki Choi, Yun Hee Baek, Min-Suk Song |
| 150 |
[GO] |
2022―Oct―05 |
Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study |
Yuao Zhu, Joe Binder, Irina Yurgelonis, Devendra Rai, Sarah Lazarro, Chester Costales, Keith Kobylarz, Patricia McMonagle, Claire M. Steppan, Lisa Aschenbrenner, Annaliesa S. Anderson, Rhonda D. Cardin |
| 151 |
[GO] |
2022―Sep―23 |
Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro |
Ling Ma, Quanjie Li, Yongli Xie, Dongrong Yi, Saisai Guo, Fei Guo, Jing Wang, Long Yang, Shan Cen |
| 152 |
[GO] |
2022―Aug―28 |
Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19 |
James F. Demarest, Maryline Kienle, RuthMabel Boytz, Mary Ayres, Eun Jung Kim, Justin J. Patten, Donghoon Chung, Varsha Gandhi, Robert Davey, David B. Sykes, Nadim Shohdy, John C. Pottage, Vikram S. Kumar |
| 153 |
[GO] |
2022―Aug―17 |
Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro |
Lian Lu, Yun Peng, Huiqiao Yao, Yanqun Wang, Jinyu Li, Yang Yang, Zhonghui Lin |
| 154 |
[GO] |
2022―Jul―31 |
Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants |
Minchao Li, Jiaoshan Chen, Yajie Liu, Jin Zhao, Yanjun Li, Yunqi Hu, Yaoqing Chen, Litao Sun, Yuelong Shu, Fengling Feng, Caijun Sun |
| 155 |
[GO] |
2022―Jul―11 |
Allosteric inhibitors of the main protease of SARS-CoV-2 |
Subodh Kumar Samrat, Jimin Xu, Xuping Xie, Eleonora Gianti, Haiying Chen, Jing Zou, Jason G. Pattis, Khaled Elokely, Hyun Lee, Zhong Li, Michael L. Klein, Pei-Yong Shi, Jia Zhou, Hongmin Li |
| 156 |
[GO] |
2022―Jul―04 |
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 |
Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Hideki Ebihara, Tadaki Suzuki, Maeda Ken, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi |
| 157 |
[GO] |
2022―Jul―04 |
Hydroxypropyl-beta-cyclodextrin (HP-BCD) inhibits SARS-CoV-2 replication and virus-induced inflammatory cytokines |
Bruno Braz Bezerra, Gustavo Peixoto Duarte da Silva, Sharton Vinicius Antunes Coelho, Isadora Alonso Correa, Marcos Romario Matos de Souza, Keylla Vitória Gomes Macedo, Bruna Machado Matos, Amilcar Tanuri, Flavio Lemos Matassoli, Luciana Jesus da Costa, James E.K. Hildreth, Luciana Barros de Arruda |
| 158 |
[GO] |
2022―Jun―29 |
Inhibition of a broad range of SARS-CoV-2 variants by antiviral phytochemicals in hACE2 mice |
Eun-Ha Kim, Ba Wool Lee, Byeol Ryu, Hyo Moon Cho, Se-Mi Kim, Seung-Gyu Jang, Mark Anthony B. Casel, Rare Rollon, Ji-Seung Yoo, Haryoung Poo, Won Keun Oh, Young Ki Choi |
| 159 |
[GO] |
2022―Jun―27 |
A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera |
Chotiwat Seephetdee, Kanit Bhukhai, Nattawut Buasri, Puttipatch Leelukkanaveera, Pat Lerdwattanasombat, Suwimon Manopwisedjaroen, Nut Phueakphud, Sakonwan Kuhaudomlarp, Eduardo Olmedillas, Erica Ollmann Saphire, Arunee Thitithanyanont, Suradej Hongeng, Patompon Wongtrakoongate |
| 160 |
[GO] |
2022―Jun―21 |
Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies |
Marwah Karim, Sirle Saul, Luca Ghita, Malaya Kumar Sahoo, Chengjin Ye, Nishank Bhalla, Chieh Wen Lo, Jing Jin, Jun-Gyu Park, Belén Martinez-Gualda, Michael Patrick East, Gary L. Johnson, Benjamin A. Pinsky, Luis Martinez-Sobrido, Christopher R.M. Asquith, Aarthi Narayanan, Steven De Jonghe, Shirit Einav |
| 161 |
[GO] |
2022―Jun―19 |
Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters |
Minmin Zhou, Yang Liu, Junyuan Cao, Siqi Dong, Yuxia Hou, Yan Yu, Qiuyan Zhang, Yueli Zhang, Xiaoying Jia, Bo Zhang, Gengfu Xiao, Gang Li, Wei Wang |
| 162 |
[GO] |
2022―Jun―16 |
Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay |
Sergio Hernández, Mikael Feracci, Carolina Trajano De Jesus, Priscila El Kazzi, Rafik Kaci, Laura Garlatti, Clemence Mondielli, Fabrice Bailly, Philippe Cotelle, Franck Touret, Xavier de Lamballerie, Bruno Coutard, Etienne Decroly, Bruno Canard, François Ferron, Karine Alvarez |
| 163 |
[GO] |
2022―Jun―10 |
Conserved coronavirus proteins as targets of broad-spectrum antivirals |
Cleber C. Melo-Filho, Tesia Bobrowski, Holli-Joi Martin, Zoe Sessions, Konstantin Popov, Nathaniel J. Moorman, Ralph S. Baric, Eugene N. Muratov, Alexander Tropsha |
| 164 |
[GO] |
2022―Jun―07 |
Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization |
Beatrice Mercorelli, Jenny Desantis, Marta Celegato, Alessandro Bazzacco, Lydia Siragusa, Paolo Benedetti, Michela Eleuteri, Federico Croci, Gabriele Cruciani, Laura Goracci, Arianna Loregian |
| 165 |
[GO] |
2022―May―28 |
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies |
Paritosh Prashar, Sonali Swain, Nisha Adhikari, Punit Aryan, Anupama Singh, Mohit Kwatra, Prabhakar B |
| 166 |
[GO] |
2022―May―21 |
Animal models for studying coronavirus infections and developing antiviral agents and vaccines |
Qisheng Lin, Chunni Lu, Yuqi Hong, Runfeng Li, Jinding Chen, Weisan Chen, Jianxin Chen |
| 167 |
[GO] |
2022―May―19 |
Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor |
Tatjana Weil, Jan Lawrenz, Alina Seidel, Jan Münch, Janis A. Müller |
| 168 |
[GO] |
2022―May―19 |
Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening |
Anu Roy, Yousef M. Alhammad, Peter McDonald, David K. Johnson, Junlin Zhuo, Sarah Wazir, Dana Ferraris, Lari Lehtiö, Anthony K.L. Leung, Anthony R. Fehr |
| 169 |
[GO] |
2022―May―18 |
SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening |
Emiel Vanhulle, Joren Stroobants, Becky Provinciael, Anita Camps, Sam Noppen, Piet Maes, Kurt Vermeire |
| 170 |
[GO] |
2022―May―07 |
Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins |
Stephen Findlay-Wilson, Linda Easterbrook, Sandra Smith, Neville Pope, Gareth Humphries, Holger Schuhmann, Didier Ngabo, Emma Rayner, Ashley David Otter, Tom Coleman, Bethany Hicks, Victoria Anne Graham, Rachel Halkerston, Kostis Apostolakis, Stephen Taylor, Susan Fotheringham, Amanda Horton, Julia Anne Tree, Matthew Wand, Roger Hewson, Stuart David Dowall |
| 171 |
[GO] |
2022―May―05 |
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection |
Jared Pitts, Darius Babusis, Meghan S. Vermillion, Raju Subramanian, Kim Barrett, Diane Lye, Bin Ma, Xiaofeng Zhao, Nicholas Riola, Xuping Xie, Adriana Kajon, Xianghan Lu, Roy Bannister, Pei-Yong Shi, Maria Toteva, Danielle P. Porter, Bill J. Smith, Tomas Cihlar, Richard Mackman, John P. Bilello |
| 172 |
[GO] |
2022―Apr―04 |
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect |
Caroline S. Foo, Rana Abdelnabi, Suzanne J.F. Kaptein, Xin Zhang, Sebastiaan ter Horst, Raf Mols, Leen Delang, Joana Rocha-Pereira, Lotte Coelmont, Pieter Leyssen, Kai Dallmeier, Valentijn Vergote, Elisabeth Heylen, Laura Vangeel, Arnab K. Chatterjee, Pieter P. Annaert, Patrick F. Augustijns, Steven De Jonghe, Dirk Jochmans, Mieke Gouwy, Seppe Cambier, Jennifer Vandooren, Paul Proost, Christine van Laer, Birgit Weynand, Johan Neyts |
| 173 |
[GO] |
2022―Mar―24 |
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants |
Mikako Ueno, Naoko Iwata-Yoshikawa, Akihito Matsunaga, Tadashi Okamura, Sho Saito, Shinobu Ashida, Isao Yoshida, Mami Nagashima, Hiroyuki Asakura, Yuu I. Yaoita, Jun Suzuki, Kenji Sadamasu, Kazuhisa Yoshimura, Satoshi Kutsuna, Nozomi Shiwa-Sudo, Noriyo Nagata, Tadaki Suzuki, Akinori Suzuki, Miwa Okamoto, Moto Kimura, Norio Ohmagari, Ryu Miura, Yukihito Ishizaka |
| 174 |
[GO] |
2022―Mar―13 |
Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain |
Guan-Chun Lai, Tai-Ling Chao, Shiau-Yu Lin, Han-Chieh Kao, Ya-Min Tsai, De-Chao Lu, Yi-Wei Chiang, Sui-Yuan Chang, Shih-Chung Chang |
| 175 |
[GO] |
2022―Mar―11 |
Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2 |
Selina Pasquero, Francesca Gugliesi, Gloria Griffante, Valentina Dell’Oste, Matteo Biolatti, Camilla Albano, Greta Bajetto, Serena Delbue, Lucia Signorini, Maria Dolci, Santo Landolfo, Marco De Andrea |
| 176 |
[GO] |
2022―Mar―09 |
Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors. |
M.D. Scholle, P. O'Kane, S. Dib, Z.A. Gurard-Levin |
| 177 |
[GO] |
2022―Mar―09 |
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors |
K.Y. Chen, T. Krischuns, L.Ortega Varga, E. Harigua-Souiai, S. Paisant, A. Zettor, J. Chiaravalli, A. Delpal, D. Courtney, A. O'Brien, S.C. Baker, E. Decroly, C. Isel, F. Agou, Y. Jacob, A. Blondel, N. Naffakh |
| 178 |
[GO] |
2022―Mar―07 |
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening |
Tomohisa Tanaka, Akatsuki Saito, Tatsuya Suzuki, Yoichi Miyamoto, Kazuo Takayama, Toru Okamoto, Kohji Moriishi |
| 179 |
[GO] |
2022―Feb―28 |
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern |
Tsung-I Tsai, Jahan S. Khalili, Mark Gilchrist, Andrew B. Waight, Daniella Cohen, Shi Zhuo, Yong Zhang, Muran Ding, Hai Zhu, Amanda Nga-Sze Mak, Yi Zhu, Dennis R. Goulet |
| 180 |
[GO] |
2022―Jan―29 |
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis |
Jianyuan Zhao, Qian Liu, Dongrong Yi, Quanjie Li, SaiSai Guo, Ling Ma, Yongxin Zhang, Dongxin Dong, Fei Guo, Zhenlong Liu, Tao Wei, Xiaoyu Li, Shan Cen |
| 181 |
[GO] |
2022―Jan―24 |
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern |
Laura Vangeel, Winston Chiu, Steven De Jonghe, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Pieter Leyssen, Johan Neyts, Dirk Jochmans |
| 182 |
[GO] |
2022―Jan―21 |
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters |
Rana Abdelnabi, Caroline S. Foo, Xin Zhang, Viktor Lemmens, Piet Maes, Bram Slechten, Joren Raymenants, Emmanuel André, Birgit Weynand, Kai Dallemier, Johan Neyts |
| 183 |
[GO] |
2022―Jan―13 |
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis |
Daniele Focosi, Fabrizio Maggi, Scott McConnell, Arturo Casadevall |
| 184 |
[GO] |
2022―Jan―13 |
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2 |
Brandi N. Williamson, Lizzette Pérez-Pérez, Benjamin Schwarz, Friederike Feldmann, Myndi G. Holbrook, Manmeet Singh, Diane S. Lye, Darius Babusis, Raju Subramanian, Elaine Haddock, Atsushi Okumura, Patrick W. Hanley, Jamie Lovaglio, Catharine M. Bosio, Danielle P. Porter, Tomas Cihlar, Richard L. Mackman, Greg Saturday, Emmie de Wit |
| 185 |
[GO] |
2021―Dec―29 |
S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants |
Ram Kumar, Nitin Khandelwal, Yogesh Chander, Himanshu Nagori, Assim Verma, Aditya Barua, Bhagraj Godara, Yash Pal, Baldev R. Gulati, Bhupendra N. Tripathi, Sanjay Barua, Naveen Kumar |
| 186 |
[GO] |
2021―Dec―18 |
COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference |
Jennifer L. McKimm-Breschkin, Alan J. Hay, Bin Cao, Rebecca J. Cox, Jake Dunning, Ann C. Moen, Daniel Olsen, Andrés Pizzorno, Frederick G. Hayden |
| 187 |
[GO] |
2021―Nov―24 |
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model |
Maxime Cochin, Franck Touret, Jean-Sélim Driouich, Gregory Moureau, Paul-Rémi Petit, Caroline Laprie, Caroline Solas, Xavier de Lamballerie, Antoine Nougairède |
| 188 |
[GO] |
2021―Nov―18 |
2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors |
Jianyuan Zhao, Guoning Zhang, Yongxin Zhang, Dongrong Yi, Quanjie Li, Ling Ma, SaiSai Guo, Xiaoyu Li, Fei Guo, Rongtuan Lin, Gia Luu, Zhenlong Liu, Yucheng Wang, Shan Cen |
| 189 |
[GO] |
2021―Nov―10 |
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein |
Hristo L. Svilenov, Julia Sacherl, Alwin Reiter, Lisa S. Wolff, Cho-Chin Cheng, Marcel Stern, Vincent Grass, Martin Feuerherd, Frank-Peter Wachs, Nicole Simonavicius, Susanne Pippig, Florian Wolschin, Oliver T. Keppler, Johannes Buchner, Carsten Brockmeyer, Ulrike Protzer |
| 190 |
[GO] |
2021―Nov―08 |
Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies |
Hongyu Qiu, Xin-Yong Yuan, Teresa Cabral, Kathy Manguiat, Alyssia Robinson, Heidi Wood, Chris Grant, Peter McQueen, Garrett Westmacott, Daniel R. Beniac, Lisa Lin, Michael Carpenter, Darwyn Kobasa, Tom Gräfenhan |
| 191 |
[GO] |
2021―Oct―21 |
Inhibition of endocytosis of porcine reproductive and respiratory syndrome virus by rottlerin and its potential prophylactic administration in piglets |
Yeong-Lim Kang, Changin Oh, So-Hyun Ahn, Jong-Chul Choi, Hwi-Yeon Choi, Sang-Won Lee, In-Soo Choi, Chang-Seon Song, Joong-Bok Lee, Seung-Yong Park |
| 192 |
[GO] |
2021―Oct―08 |
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement |
Ying-Ting Wang, Robert D. Allen, Kenneth Kim, Norazizah Shafee, Andrew J. Gonzalez, Michael N. Nguyen, Kristen M. Valentine, Xia Cao, Lucy Lu, Chin-I Pai, Sachi Johnson, Lisa Kerwin, Heyue Zhou, Yanliang Zhang, Sujan Shresta |
| 193 |
[GO] |
2021―Oct―07 |
A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition |
Rama Dey-Rao, George R. Smith, Uddhav Timilsina, Zackary Falls, Ram Samudrala, Spyridon Stavrou, Thomas Melendy |
| 194 |
[GO] |
2021―Aug―24 |
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target |
Isabel García-Dorival, Miguel Ángel Cuesta-Geijo, Lucía Barrado-Gil, Inmaculada Galindo, Urtzi Garaigorta, Jesús Urquiza, Ana del Puerto, Nuria E. Campillo, Ana Martínez, Pablo Gastaminza, Carmen Gil, Covadonga Alonso |
| 195 |
[GO] |
2021―Aug―09 |
Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells |
Olivier Escaffre, Alexander N. Freiberg |
| 196 |
[GO] |
2021―Aug―08 |
A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency |
Adam Leach, F. Tudor Ilca, Zulaikha Akbar, Mathieu Ferrari, Emma M. Bentley, Giada Mattiuzzo, Shimobi Onuoha, Ami Miller, Hanif Ali, Terence H. Rabbitts |
| 197 |
[GO] |
2021―Jul―23 |
Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase |
Renata Kasprzyk, Tomasz J. Spiewla, Miroslaw Smietanski, Sebastian Golojuch, Laura Vangeel, Steven De Jonghe, Dirk Jochmans, Johan Neyts, Joanna Kowalska, Jacek Jemielity |
| 198 |
[GO] |
2021―Jul―12 |
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 |
Franck Touret, Jean-Sélim Driouich, Maxime Cochin, Paul Rémi Petit, Magali Gilles, Karine Barthélémy, Grégory Moureau, Francois-Xavier Mahon, Denis Malvy, Caroline Solas, Xavier de Lamballerie, Antoine Nougairède |
| 199 |
[GO] |
2021―Jul―08 |
A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection |
Esther S. Gan, Ayesa Syenina, Martin Linster, Benson Ng, Summer L. Zhang, Satoru Watanabe, Ravisankar Rajarethinam, Hwee Cheng Tan, Gavin JD. Smith, Eng Eong Ooi |
| 200 |
[GO] |
2021―Jun―26 |
A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents |
Thuc Nguyen Dan Do, Kim Donckers, Laura Vangeel, Arnab K. Chatterjee, Philippe A. Gallay, Michael D. Bobardt, John P. Bilello, Tomas Cihlar, Steven De Jonghe, Johan Neyts, Dirk Jochmans |
| 201 |
[GO] |
2021―Jun―19 |
Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo |
Trinayan Kashyap, Jackelyn Murray, Christopher J. Walker, Hua Chang, Sharon Tamir, Bing Hou, Sharon Shacham, Michael G. Kauffman, Ralph A. Tripp, Yosef Landesman |
| 202 |
[GO] |
2021―May―16 |
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro |
Jeremy R.A. Paull, Graham P. Heery, Michael D. Bobardt, Alex Castellarnau, Carolyn A. Luscombe, Jacinth K. Fairley, Philippe A. Gallay |
| 203 |
[GO] |
2021―Apr―21 |
A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase |
Jianyuan Zhao, SaiSai Guo, Dongrong Yi, Quanjie Li, Ling Ma, Yongxin Zhang, Jing Wang, Xiaoyu Li, Fei Guo, Rongtuan Lin, Chen Liang, Zhenlong Liu, Shan Cen |
| 204 |
[GO] |
2021―Apr―17 |
Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CLpro |
Ruikun Du, Laura Cooper, Zinuo Chen, Hyun Lee, Lijun Rong, Qinghua Cui |
| 205 |
[GO] |
2021―Mar―27 |
Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection |
Fabiola Ciccosanti, Martina Di Rienzo, Alessandra Romagnoli, Francesca Colavita, Giulia Refolo, Concetta Castilletti, Chiara Agrati, Annalaura Brai, Fabrizio Manetti, Lorenzo Botta, Maria Rosaria Capobianchi, Giuseppe Ippolito, Mauro Piacentini, Gian Maria Fimia |
| 206 |
[GO] |
2021―Mar―11 |
Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E |
Ram Kumar, Mohammad Afsar, Nitin Khandelwal, Yogesh Chander, Thachamvally Riyesh, Ramesh Kumar Dedar, Baldev R. Gulati, Yash Pal, Sanjay Barua, Bhupendra N. Tripathi, Tanweer Hussain, Naveen Kumar |
| 207 |
[GO] |
2021―Mar―11 |
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors |
Mario Milani, Manuela Donalisio, Rafaela Milan Bonotto, Edoardo Schneider, Irene Arduino, Francesco Boni, David Lembo, Alessandro Marcello, Eloise Mastrangelo |
| 208 |
[GO] |
2021―Feb―06 |
Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir |
Ross Martin, Jiani Li, Aiyippa Parvangada, Jason Perry, Tomas Cihlar, Hongmei Mo, Danielle Porter, Evguenia Svarovskaia |
| 209 |
[GO] |
2021―Jan―27 |
Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development |
Cheng Liu, Sandro Boland, Michael D. Scholle, Dorothee Bardiot, Arnaud Marchand, Patrick Chaltin, Lawrence M. Blatt, Leonid Beigelman, Julian A. Symons, Pierre Raboisson, Zachary A. Gurard-Levin, Koen Vandyck, Jerome Deval |
| 210 |
[GO] |
2021―Jan―13 |
Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system |
Qingyuan Zhu, Yaling Zhang, Li Wang, Xiangyu Yao, Daitze Wu, Junjun Cheng, Xiaoyu Pan, Haixia Liu, Zhipeng Yan, Lu Gao |
| 211 |
[GO] |
2021―Jan―08 |
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo |
Christin Müller, Wiebke Obermann, Nadja Karl, Hans-Guido Wendel, Gaspar Taroncher-Oldenburg, Stephan Pleschka, Roland K. Hartmann, Arnold Grünweller, John Ziebuhr |
| 212 |
[GO] |
2020―Dec―10 |
Antiviral activity against Middle East Respiratory Syndrome Coronavirus by Montelukast, an anti-asthma drug |
Hanjie Jonathan Gan, Amaravadhi Harikishore, Jihye Lee, Sangeun Jeon, Sreekanth Rajan, Ming Wei Chen, Jun Long Neo, Seungtaek Kim, Ho Sup Yoon |
| 213 |
[GO] |
2020―Nov―25 |
Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro |
Esben B. Svenningsen, Jacob Thyrsted, Julia Blay-Cadanet, Han Liu, Shaoquan Lin, Jaime Moyano Villameriel, David Olagnier, Manja Idorn, Søren R. Paludan, Christian K. Holm, Thomas B. Poulsen |
| 214 |
[GO] |
2020―Nov―17 |
A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2 |
Yang Zhang, Wuhui Song, Shuiye Chen, Zhenghong Yuan, Zhigang Yi |
| 215 |
[GO] |
2020―Oct―19 |
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes |
Seong Woo Choi, Jin Soo Shin, Soon-Jung Park, Eunhye Jung, Yun-Gwi Park, Jiho Lee, Sung Joon Kim, Hun-Jun Park, Jung-Hoon Lee, Sung-Min Park, Sung-Hwan Moon, Kiwon Ban, Yun Young Go |
| 216 |
[GO] |
2020―Sep―19 |
Cryptotanshinone Protects Porcine Alveolar Macrophages from Infection with Porcine Reproductive and Respiratory Syndrome Virus |
Chang Huang, Jiaqi Zhu, Ling Wang, Alexander Chu, Yexuan Yin, Kaneha Vali, Antonio Garmendia, Young Tang |
| 217 |
[GO] |
2020―Sep―07 |
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses |
Sirin Theerawatanasirikul, Chih Jung Kuo, Nanthawan Phecharat, Jullada Chootip, Chalermpol Lekcharoensuk, Porntippa Lekcharoensuk |
| 218 |
[GO] |
2020―Sep―06 |
Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry |
Zachary A. Gurard-Levin, Cheng Liu, Andreas Jekle, Ruchika Jaisinghani, Suping Ren, Koen Vandyck, Dirk Jochmans, Pieter Leyssen, Johan Neyts, Lawrence M. Blatt, Leonid Beigelman, Julian A. Symons, Pierre Raboisson, Michael D. Scholle, Jerome Deval |
| 219 |
[GO] |
2020―Jul―30 |
The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro |
Mika Okamoto, Masaaki Toyama, Masanori Baba |
| 220 |
[GO] |
2020―Jul―29 |
An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection |
Carina Conzelmann, Andrea Gilg, Rüdiger Groß, Desiree Schütz, Nico Preising, Ludger Ständker, Bernd Jahrsdörfer, Hubert Schrezenmeier, Konstantin M.J. Sparrer, Thomas Stamminger, Steffen Stenger, Jan Münch, Janis A. Müller |
| 221 |
[GO] |
2020―Jul―15 |
In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2 |
Andrés Pizzorno, Blandine Padey, Julia Dubois, Thomas Julien, Aurélien Traversier, Victoria Dulière, Pauline Brun, Bruno Lina, Manuel Rosa-Calatrava, Olivier Terrier |
| 222 |
[GO] |
2020―Jul―15 |
Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors |
Pierre Gallian, Boris Pastorino, Pascal Morel, Jacques Chiaroni, Laetitia Ninove, Xavier de Lamballerie |
| 223 |
[GO] |
2020―Jul―10 |
Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection |
Nicolas Venisse, Gilles Peytavin, Stephane Bouchet, Marie-Claude Gagnieu, Rodolphe Garraffo, Romain Guilhaumou, Caroline Solas |
| 224 |
[GO] |
2020―Jul―10 |
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions |
So Young Kim, Weihua Jin, Amika Sood, David W. Montgomery, Oliver C. Grant, Mark M. Fuster, Li Fu, Jonathan S. Dordick, Robert J. Woods, Fuming Zhang, Robert J. Linhardt |
| 225 |
[GO] |
2020―Jul―10 |
Immunoglobulin fragment F(ab’)2 against RBD potently neutralizes SARS-CoV-2 in vitro |
Xiaoyan Pan, Pengfei Zhou, Tiejiong Fan, Yan Wu, Jing Zhang, Xiaoyue Shi, Weijuan Shang, Lijuan Fang, Xiaming Jiang, Jian Shi, Yuan Sun, Shaojuan Zhao, Rui Gong, Ze Chen, Gengfu Xiao |
| 226 |
[GO] |
2020―Jun―19 |
The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium |
Yung Jin Jeon, Chan Hee Gil, Ara Jo, Jina Won, Sujin Kim, Hyun Jik Kim |
| 227 |
[GO] |
2020―Jun―18 |
A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses that Cause SARS and COVID-19 |
Steffen Jockusch, Chuanjuan Tao, Xiaoxu Li, Thomas K. Anderson, Minchen Chien, Shiv Kumar, James J. Russo, Robert N. Kirchdoerfer, Jingyue Ju |
| 228 |
[GO] |
2020―May―13 |
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2 |
Wanbo Tai, Xiujuan Zhang, Yuxian He, Shibo Jiang, Lanying Du |
| 229 |
[GO] |
2020―Apr―29 |
Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection |
Emily Mantlo, Natalya Bukreyeva, Junki Maruyama, Slobodan Paessler, Cheng Huang |
| 230 |
[GO] |
2020―Apr―21 |
Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses |
Mike Bray, Craig Rayner, François Noël, David Jans, Kylie Wagstaff |
| 231 |
[GO] |
2020―Apr―10 |
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites |
Ashleigh Shannon, Nhung Thi-Tuyet Le, Barbara Selisko, Cecilia Eydoux, Karine Alvarez, Jean-Claude Guillemot, Etienne Decroly, Olve Peersen, Francois Ferron, Bruno Canard |
| 232 |
[GO] |
2020―Apr―07 |
Type 1 interferons as a potential treatment against COVID-19 |
Erwan Sallard, François-Xavier Lescure, Yazdan Yazdanpanah, France Mentre, Nathan Peiffer-Smadja |
| 233 |
[GO] |
2020―Apr―06 |
Coronavirus membrane fusion mechanism offers as a potential target for antiviral development |
Tiffany Tang, Miya Bidon, Javier A. Jaimes, Gary R. Whittaker, Susan Daniel |
| 234 |
[GO] |
2020―Apr―03 |
The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro |
Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff |
| 235 |
[GO] |
2020―Apr―03 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro |
Ka-Tim Choy, Alvina Yin-Lam Wong, Prathanporn Kaewpreedee, Sin-Fun Sia, Dongdong Chen, Kenrie Pui Yan Hui, Daniel Ka Wing Chu, Michael Chi Wai Chan, Peter Pak-Hang Cheung, Xuhui Huang, Malik Peiris, Hui-Ling Yen |
| 236 |
[GO] |
2020―Mar―06 |
Of chloroquine and COVID-19 |
Franck Touret, Xavier de Lamballerie |
| 237 |
[GO] |
2020―Mar―01 |
A potential role for integrins in host cell entry by SARS-CoV-2 |
Christian JA Sigrist, Alan Bridge, Philippe Le Mercier |
| 238 |
[GO] |
2020―Feb―27 |
Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus |
Hongyu Qiu, Hanne Andersen, E. Bart Tarbet, F. Salih Muhammad, Trevor Carnelley, Russell Pronyk, Douglas Barker, Shantha Kodihalli |
| 239 |
[GO] |
2020―Feb―10 |
The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade |
B. Coutard, C. Valle, X. de Lamballerie, B. Canard, N.G. Seidah, E. Decroly |
|
